47.10

0.86% -0.41

After Hours: 47.165 0.065 +0.14%

Janux Therapeutics Inc (JANX)

Overview News Price History Option Chain Financials Discussions Forecast

Janux Therapeutics Inc stock is currently priced at $47.10, with a 24-hour trading volume of 587.58K. It has seen a -0.86% decreased in the last 24 hours and a -1.79% declined in the past month. The chart indicates a potential bearish trend, as the stock is below the $47.44 pivot point. If it approaches the $46.64 support level, significant changes may occur.

Previous Close:

$47.51

Open:

$47.76

24h Volume:

587.58K

Market Cap:

$2.44B

Revenue:

$8.08M

Net Income/Loss:

$-58.29M

P/E Ratio:

-28.90

EPS:

-1.63

Net Cash Flow:

$-52.43M

1W Performance:

-3.72%

1M Performance:

-1.79%

6M Performance:

+442.63%

1Y Performance:

+292.50%

1D Range:

$46.79

$47.97

52W Range:

$5.65

$65.60

Janux Therapeutics Inc Stock (JANX) Company Profile

Name

Janux Therapeutics Inc

Sector

Healthcare (1209)

Industry

Biotechnology (699)

Phone

858-750-4700

Address

11099 North Torrey Pines Road, Suite 290, La Jolla

Employee

Twitter

Next Earnings Date

2024-05-10

Latest SEC Filings

JANX's Discussions on Twitter

Janux Therapeutics Inc Stock (JANX) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-06-23	Initiated	Wedbush	Outperform
Nov-14-22	Initiated	William Blair	Outperform

Janux Therapeutics Inc Stock (JANX) Latest News

Janux Therapeutics (NASDAQ:JANX) investors are sitting on a loss of 44% if they invested a year ago - Yahoo New Zealand News

Yahoo New Zealand News

Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Could Be 28% Below Their Intrinsic Value Estimate - Yahoo Movies UK

Yahoo Movies UK

HC Wainwright Equities Analysts Lower Earnings Estimates for Janux Therapeutics, Inc. (NASDAQ:JANX) - MarketBeat

MarketBeat

Janux Therapeutics, Inc. (NASDAQ:JANX) Forecasted to Post Q2 2024 Earnings of ($0.38) Per Share - Defense World

Defense World

Janux Therapeutics (NASDAQ:JANX) PT Raised to $63.00 - Defense World

Defense World

Janux Therapeutics (NASDAQ:JANX) Trading Down 3.1% - MarketBeat

MarketBeat

Janux Therapeutics Inc Stock (JANX) Financials Data

Janux Therapeutics Inc (JANX) Revenue 2024

JANX reported a revenue (TTM) of $8.08 million for the quarter ending December 31, 2023, a -6.14% decline year-over-year.

Janux Therapeutics Inc (JANX) Net Income 2024

JANX net income (TTM) was -$58.29 million for the quarter ending December 31, 2023, a +7.56% increase year-over-year.

Janux Therapeutics Inc (JANX) Cash Flow 2024

JANX recorded a free cash flow (TTM) of -$52.42 million for the quarter ending December 31, 2023, a -6.19% decrease year-over-year.

Janux Therapeutics Inc (JANX) Earnings per Share 2024

JANX earnings per share (TTM) was -$1.33 for the quarter ending December 31, 2023, a +12.50% growth year-over-year.

Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. It is also developing a Tumor Activated Immunomodulator (TRACIr) costimulatory bispecific product candidate against programmed death-ligand 1 and CD28 designed to improve the anti-tumor activity of T cells. The company was incorporated in 2017 and is headquartered in La Jolla, California.